bpc-157 neuroprotective effects Peptide Therapy in York & Hanover PA BPC-157 vs IGF-1: Best Peptide

10.1152/japplphysiol.00945.2010 22 CollenD

This is preclinical data only, but it signals potential applications beyond fat metabolism that researchers have begun exploring

You're not missing the "right supplement." You might be missing the right strategy

Unlike treatments designed specifically for weight management, BPC-157 does not seem to: Reduce appetite Increase feelings of fullness Trigger fat burning Significantly increase calorie expenditure Instead, any potential weight-related benefits are generally believed to occur indirectly through improvements in recovery, mobility, and overall physical function

consistent ~12-15% weight loss at 68 weeks Compound Tirzepatide (Zepbound) Class GIP/GLP-1 dual agonist FDA Status FDA-approved for chronic weight management Evidence Strength Phase 3 RCTs

Laboratory Testing We conduct necessary laboratory tests, such as vitamin B12 levels, liver function tests, and metabolic tests, to understand how patients will process and react to the treatment